Abnova Taiwan Corp (4133) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abnova Taiwan Corp (4133) has a cash flow conversion efficiency ratio of 0.010x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$12.73 Million ≈ $400.97K USD) by net assets (NT$1.26 Billion ≈ $39.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review 4133 FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
Abnova Taiwan Corp - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Abnova Taiwan Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see how much is Abnova Taiwan Corp worth for the company's overall valuation and market capitalisation.
Abnova Taiwan Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abnova Taiwan Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hojeon Ltd
KO:111110
|
0.074x |
|
FFI Holdings Ltd
AU:FFI
|
-0.121x |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
0.085x |
|
China Television Co
TW:9928
|
-0.016x |
|
HARMONEY CORP. LTD
F:6DR
|
N/A |
|
JASTECH Ltd
KQ:090470
|
0.083x |
|
Thai Textile Industry Public Company Limited
BK:TTI
|
0.013x |
|
Aeries Technology Inc.
NASDAQ:AERT
|
-0.778x |
Annual Cash Flow Conversion Efficiency for Abnova Taiwan Corp (2009–2025)
The table below shows the annual cash flow conversion efficiency of Abnova Taiwan Corp from 2009 to 2025. View current stock price of Abnova Taiwan Corp for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.26 Billion ≈ $39.59 Million |
NT$-4.19 Million ≈ $-132.07K |
-0.003x | -108.59% |
| 2024-12-31 | NT$1.31 Billion ≈ $41.25 Million |
NT$50.85 Million ≈ $1.60 Million |
0.039x | -34.46% |
| 2023-12-31 | NT$1.29 Billion ≈ $40.53 Million |
NT$76.22 Million ≈ $2.40 Million |
0.059x | -42.17% |
| 2022-12-31 | NT$1.29 Billion ≈ $40.70 Million |
NT$132.37 Million ≈ $4.17 Million |
0.102x | +33.67% |
| 2021-12-31 | NT$1.21 Billion ≈ $38.18 Million |
NT$92.88 Million ≈ $2.93 Million |
0.077x | -11.85% |
| 2020-12-31 | NT$1.21 Billion ≈ $38.16 Million |
NT$105.30 Million ≈ $3.32 Million |
0.087x | +39.14% |
| 2019-12-31 | NT$1.19 Billion ≈ $37.57 Million |
NT$74.51 Million ≈ $2.35 Million |
0.062x | -13.99% |
| 2018-12-31 | NT$1.23 Billion ≈ $38.66 Million |
NT$89.17 Million ≈ $2.81 Million |
0.073x | +31.77% |
| 2017-12-31 | NT$1.22 Billion ≈ $38.59 Million |
NT$67.53 Million ≈ $2.13 Million |
0.055x | -9.84% |
| 2016-12-31 | NT$1.18 Billion ≈ $37.06 Million |
NT$71.94 Million ≈ $2.27 Million |
0.061x | -2.83% |
| 2015-12-31 | NT$1.17 Billion ≈ $36.76 Million |
NT$73.43 Million ≈ $2.31 Million |
0.063x | -17.82% |
| 2014-12-31 | NT$1.23 Billion ≈ $38.74 Million |
NT$94.18 Million ≈ $2.97 Million |
0.077x | -14.21% |
| 2013-12-31 | NT$1.23 Billion ≈ $38.74 Million |
NT$109.78 Million ≈ $3.46 Million |
0.089x | +44.31% |
| 2012-12-31 | NT$1.23 Billion ≈ $38.72 Million |
NT$76.02 Million ≈ $2.40 Million |
0.062x | -41.44% |
| 2011-12-31 | NT$1.27 Billion ≈ $40.03 Million |
NT$134.22 Million ≈ $4.23 Million |
0.106x | +17.26% |
| 2010-12-31 | NT$1.27 Billion ≈ $40.01 Million |
NT$114.40 Million ≈ $3.60 Million |
0.090x | +71.09% |
| 2009-12-31 | NT$1.21 Billion ≈ $38.13 Million |
NT$63.72 Million ≈ $2.01 Million |
0.053x | -- |
About Abnova Taiwan Corp
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems,… Read more